Prediction of postoperative disease-free survival and brain metastasis for HER2-positive breast cancer patients treated with neoadjuvant chemotherapy plus trastuzumab using a machine learning algorithm
ConclusionsThe DFS and BM models have a high accuracy to predict prognosis among HER2-positive patients treated with NAC plus trastuzumab. Our models can help optimize adjuvant therapy and postoperative surveillance.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
More News: Brain | Brain Cancers | Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | HER2 | Herceptin | Learning | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Neurology | Study | Universities & Medical Training